TP-05 for Tick Prevention in Healthy Subjects
What You Need to Know Before You Apply
What is the purpose of this trial?
This trial tests TP-05, a medication aimed at killing ticks that attach to human skin. Participants will have ticks placed on their skin and will receive either TP-05 or another treatment. The study will measure how well TP-05 kills the ticks by affecting their nervous system.
Will I have to stop taking my current medications?
The trial requires that you stop taking most non-prescription or prescription drugs, except for hormonal contraceptives, hormone replacement therapy, and acetaminophen, at least 7 days before starting the study. If the drug is a potential enzyme inducer, you need to stop 14 days before. Please check with the study team for specific guidance on your medications.
Who Is on the Research Team?
Yoav Golan
Principal Investigator
Tufts Medical Center
Linden Hu, MD
Principal Investigator
Tufts University School of Medicine
Kavita Dhamdhere, MD, PhD
Principal Investigator
Tarsus Pharmaceuticals, Inc.
Are You a Good Fit for This Trial?
This trial is for non-smoking or ex-smoking healthy adults aged 18-59 with a BMI of 18-32 kg/m^2. Participants must be in good health, not have significant medical conditions, and agree to use contraception. They should be willing to follow study procedures and not have any history of severe reactions to tick bites or certain chronic diseases.Inclusion Criteria
Exclusion Criteria
Timeline for a Trial Participant
Screening
Participants are screened for eligibility to participate in the trial
Treatment
Participants receive either low dose or high dose of TP-05 or placebo, with tick placement and mortality assessment
Follow-up
Participants are monitored for safety and effectiveness after treatment, including additional safety and PK visits
What Are the Treatments Tested in This Trial?
Interventions
- TP-05
Find a Clinic Near You
Who Is Running the Clinical Trial?
Tarsus Pharmaceuticals, Inc.
Lead Sponsor